EMA Authorised: Xigduo (metformin hydrochloride;dapagliflozin propanediol monohydrate) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Xigduo (metformin hydrochloride and dapagliflozin propanediol monohydrate) for the treatment of Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Xigduo

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: AstraZeneca AB. Decision date: 12/03/2026